从其他肿瘤中学习：胆管癌的进展途径与挑战应对
Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma.
作者信息
Tesini Giulia, Braconi Chiara, Rimassa Lorenza, Macias Rocio I R
机构信息
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy.
School of Cancer Sciences, University of Glasgow, Switchback Rd., Glasgow G61 1QH, UK.
出版信息
Cancers (Basel). 2025 Jan 6;17(1):156. doi: 10.3390/cancers17010156.
Abstract
Cholangiocarcinoma (CCA) is a group of complex and heterogeneous tumors originating from the epithelial cells of bile ducts that can occur in intrahepatic, perihilar, or distal localizations [...].
摘要
胆管癌（CCA）是一组起源于胆管上皮细胞的复杂且异质性肿瘤，可发生于肝内、肝门周围或远端部位[...]。
相似文献
1
Learning from Other Tumors: Pathways for Progress and Overcoming Challenges in Cholangiocarcinoma.从其他肿瘤中学习：胆管癌的进展途径与挑战应对
Cancers (Basel). 2025 Jan 6;17(1):156. doi: 10.3390/cancers17010156.
2
Classification of Intrahepatic Cholangiocarcinoma into Perihilar Versus Peripheral Subtype.肝内胆管癌分为肝门周围型与肝内周围型。
Ann Surg Oncol. 2024 Feb;31(2):1232-1242. doi: 10.1245/s10434-023-14502-3. Epub 2023 Nov 6.
3
Survival of Patients with Cholangiocarcinoma Receiving Surgical Treatment in an O. viverrini Endemic Area in Thailand: A Retrospective Cohort Study.在泰国华支睾吸虫流行区接受手术治疗的胆管癌患者的生存情况：一项回顾性队列研究。
Asian Pac J Cancer Prev. 2020 Apr 1;21(4):903-909. doi: 10.31557/APJCP.2020.21.4.903.
4
Clinical presentation, diagnosis and staging of cholangiocarcinoma.胆管癌的临床表现、诊断和分期。
Liver Int. 2019 May;39 Suppl 1:98-107. doi: 10.1111/liv.14086. Epub 2019 Mar 25.
5
Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment.肝内胆管癌：管理与治疗的进展策略
Dig Liver Dis. 2024 Mar;56(3):383-393. doi: 10.1016/j.dld.2023.08.052. Epub 2023 Sep 16.
6
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.胆管癌。包括一系列肝内、肝门周围和远端肿瘤。
Ann Surg. 1996 Oct;224(4):463-73; discussion 473-5. doi: 10.1097/00000658-199610000-00005.
7
Small but mighty: How microRNAs drive the deadly progression of cholangiocarcinoma.小而强大：microRNAs 如何推动胆管癌的致命进展。
Pathol Res Pract. 2023 Jul;247:154565. doi: 10.1016/j.prp.2023.154565. Epub 2023 May 21.
8
Pathologic classification of cholangiocarcinoma: New concepts.胆管癌的病理分类：新概念
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):277-93. doi: 10.1016/j.bpg.2015.02.006. Epub 2015 Feb 17.
9
Pathogenesis, diagnosis, and management of cholangiocarcinoma.胆管癌的发病机制、诊断和治疗。
Gastroenterology. 2013 Dec;145(6):1215-29. doi: 10.1053/j.gastro.2013.10.013. Epub 2013 Oct 15.
10
Clinical treatment of cholangiocarcinoma: an updated comprehensive review.胆管癌的临床治疗：最新综合综述。
Ann Hepatol. 2022 Sep-Oct;27(5):100737. doi: 10.1016/j.aohep.2022.100737. Epub 2022 Jul 7.
本文引用的文献
1
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.基于活检和循环肿瘤DNA分析的对不可逆FGFR1-4抑制剂富替巴替尼反应和耐药的基因组关联
Ann Oncol. 2025 Apr;36(4):414-425. doi: 10.1016/j.annonc.2024.11.017. Epub 2024 Dec 11.
2
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial.阿替利珠单抗联合化疗加或不加贝伐单抗治疗晚期胆管癌：随机II期IMbrave151试验的临床和生物标志物数据
J Clin Oncol. 2025 Feb 10;43(5):545-557. doi: 10.1200/JCO.24.00337. Epub 2024 Oct 18.
3
The Search for Risk, Diagnostic, and Prognostic Biomarkers of Cholangiocarcinoma and Their Biological and Clinicopathologic Significance.胆管癌风险、诊断及预后生物标志物的探索及其生物学和临床病理意义
Am J Pathol. 2025 Mar;195(3):422-436. doi: 10.1016/j.ajpath.2024.06.013. Epub 2024 Aug 3.
4
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.度伐利尤单抗或安慰剂联合吉西他滨和顺铂治疗晚期胆道癌（TOPAZ-1）：一项随机 3 期研究的更新总生存期数据。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):694-704. doi: 10.1016/S2468-1253(24)00095-5. Epub 2024 May 29.
5
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.乐伐替尼联合帕博利珠单抗治疗既往接受过治疗的晚期卵巢癌患者：2期多队列LEAP-005研究结果
Gynecol Oncol. 2024 Jul;186:182-190. doi: 10.1016/j.ygyno.2024.04.011. Epub 2024 May 7.
6
A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening.基于无细胞游离 DNA 的血液检测用于结直肠癌筛查。
N Engl J Med. 2024 Mar 14;390(11):973-983. doi: 10.1056/NEJMoa2304714.
7
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
8
Testing for Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.检测突变以指导激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的治疗：ASCO 指南快速推荐更新。
J Clin Oncol. 2023 Jun 20;41(18):3423-3425. doi: 10.1200/JCO.23.00638. Epub 2023 May 17.
9
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
10
Anti-TIGIT therapies for solid tumors: a systematic review.抗 TIGIT 疗法治疗实体瘤：系统评价。
ESMO Open. 2023 Apr;8(2):101184. doi: 10.1016/j.esmoop.2023.101184. Epub 2023 Mar 16.
Zotero 插件